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Summary
Background.  —  No  clinical  practice  guidelines  are  available  for  the  treatment  of  heart  failureEpidemiology;
Ejection  fraction;
Beta-blockers;
ACE  inhibitors
(HF) in  patients  with  preserved  left  ventricular  ejection  fraction  (LVEF).
Aims. —  To  determine  how  cardiologists  manage  medical  treatment  in  HF  patients  after  hospital
discharge, according  to  LVEF.
Methods.  —  The  FUTURE  study  was  a  cross-sectional  survey  conducted  in  HF  outpatients  by
French private  cardiologists  between  September  2007  and  August  2008.  Patients  had  to  have
Abbreviations: ACEI, Angiotensin-Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker; COPD, Chronic Obstructive Pulmonary
Disease; ESC, European Society of Cardiology; HF, Heart Failure; HFpEF, HF patients with preserved LVEF; HFrEF, HF patients with reduced
LVEF; LVEF, Left Ventricular Ejection Fraction; NYHA, New York Heart Association.
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been  hospitalized  within  the  previous  18  months  with  a  diagnosis  of  HF.  Clinical  data  and  HF
treatments  (angiotensin-converting  enzyme  inhibitors  [ACEIs],  angiotensin  receptor  blockers
[ARBs],  beta-blockers,  diuretics  and  aldosterone  antagonists)  were  recorded  retrospectively,
with precise  information  on  drug  doses,  at  two  successive  time  points  (at  hospital  discharge
and at  the  index  consultation).  HF  treatment  was  compared  in  patients  with  reduced  (less  than
or equal  to  40%)  versus  preserved  (more  than  40%)  LVEF.
Results.  —  Completed  data  were  available  for  1137  HF  patients  enrolled  by  424  cardiologists.
Mean patient  age  was  72  ±  11  years;  LVEF  was  reduced  in  56%  and  preserved  in  44%.  The  ther-
apeutic approach  was  similar  in  the  two  groups,  both  at  hospital  discharge  and  at  the  index
consultation.  At  the  index  consultation,  HF  treatment  was:  beta-blocker  (74%);  ACEI/ARB  (83%);
loop diuretic  (86%);  aldosterone  antagonist  (31%).  The  majority  of  patients  (62%)  received  a
beta-blocker  plus  an  ACEI  or  an  ARB;  56%  reached  more  than  or  equal  to  50%  of  the  target  dose
for each  treatment.  There  were  no  major  differences  in  treatments  and  dosages  between  the
groups with  low  and  preserved  LVEF.  In  15%  of  cases  where  the  drug  dose  was  not  increased,
fear of  adverse  events  was  reported  as  the  reason.
Conclusion.  —  The  FUTURE  survey  showed  a  similar  approach  to  HF  treatment  irrespective  of
LVEF. Compared  with  previous  studies,  we  saw  an  improvement  in  the  use  of  recommended  HF
drugs, especially  beta-blockers.  However,  achievement  of  target  doses  could  be  improved.
© 2012  Published  by  Elsevier  Masson  SAS.
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Résumé
Buts.  —  Il  n’y  a  pas  de  recommandations  scientiﬁques  bien  décrites  auxquelles  le  cardiologue
peut se  référer  en  ce  qui  concerne  le  traitement  de  l’insufﬁsance  cardiaque  à  fraction  d’éjection
préservée.  Le  but  de  cette  étude  a  été  de  déterminer  la  fac¸on  dont  les  cardiologues  prennent  en
charge le  traitement  médical  des  patients  en  fonction  de  leur  FEVG  après  la  sortie  de  l’hôpital.
Méthodes.  —  FUTURE  est  un  registre  transversal  réalisé  sur  des  patients  insufﬁsants  cardiaques
ambulatoires  suivis  par  des  cardiologues  libéraux  entre  septembre  2007  et  Août  2008.  Les
patients devaient  avoir  été  hospitalisés  au  cours  des  18  mois  précédents,  avec  un  diagnostic
d’insufﬁsance  cardiaque.  Les  données  cliniques  et  le  traitement  médical  (IEC,  ARA2,  bêtablo-
quants, diurétiques  et  antagonistes  de  l’aldostérone)  ont  été  relevés  à  deux  moments  successifs
(à la  sortie  de  l’hôpital  et  à  la  consultation  d’entrée  dans  l’étude)  avec  des  informations  précises
sur les  doses  de  médicaments.
Résultats.  — Des  données  complètes  ont  été  obtenues  chez  1137  patients  insufﬁsants  cardiaques
par 424  cardiologues.  L’âge  moyen  était  de  72  ±  11  ans.  La  FEVG  était  abaissée  (inférieure
ou égale  à  40  %)  chez  56  %  et  préservée  (supérieure  à  40  %)  chez  44  %  des  patients.  À  la
sortie de  l’hôpital  aussi  bien  qu’à  la  consultation  d’entrée  dans  l’étude,  l’approche  thérapeu-
tique est  apparue  similaire  dans  les  deux  groupes.  À  la  consultation  d’entrée,  le  traitement
était :  bêtabloquants  (74  %),  IEC  ou  ARA2  (83  %),  diurétique  de  l’anse  (86  %)  et  antagonistes  de
l’aldostérone  (31  %).  La  majorité  des  patients  (62  %)  recevait  une  combinaison  de  bêtabloquant
et d’IEC  ou  ARA2  et  56  %  avait  atteint  au  moins  50  %  de  la  dose  cible  pour  chacun  des  traitements.
Il n’y  avait  pas  de  différence  majeure  dans  les  traitements  et  dans  les  doses  entre  les  deux
groupes de  patients  avec  FEVG  basse  ou  préservée.  Dans  15  %  des  cas  où  la  dose  de  médicament
n’a pas  été  augmentée,  l’explication  rapportée  était  une  crainte  des  effets  secondaires.
Conclusion.  —  Quelle  que  soit  la  FEVG,  FUTURE  montre  que  l’approche  du  traitement  de
l’insufﬁsance  cardiaque  est  similaire.  Par  rapport  aux  études  antérieures,  il  est  noté  une
amélioration  dans  l’utilisation  des  médicaments  recommandés  dans  l’insufﬁsance  cardiaque,
en particulier  les  bêtabloquants.  Toutefois,  une  amélioration  est  encore  possible  en  ce  qui
concerne les  doses  administrées.
© 2012  Publié  par  Elsevier  Masson  SAS.
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F  is  a  costly  public  health  problem  that  increases  in  preva-
ence  with  age  in  the  populations  of  western  countries  [1].
espite  advances  in  medical  strategies  in  the  treatment
f  myocardial  infarction  or  hypertension,  the  proportion  of
atients  presenting  with  HF  is  increasing,  with  an  estimated
00  to  750,000  HF  patients  in  France  [2],  at  least  10%  of
m
u
vhom  are  elderly  subjects  (aged  over  80  years).  HF  is  a
erious  and  potentially  life-threatening  disease  that  impairs
uality  of  life.  Median  survival  after  diagnosis  of  HF  does  not
xceed  4  years.Although  guidelines  and  recommendations  for  the  treat-
ent  of  chronic  HF  are  based  on  clinical  trial  results  [3],
nder  ‘‘real-life’’  conditions,  affected  populations  are  often
ery  different  from  patients  enrolled  in  clinical  trials  [4]:
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6Optimization  of  HF  treatment  after  discharge  according  to  L
they  are  generally  older  and  more  often  have  a  preserved
LVEF.  The  mean  age  of  patients  admitted  to  hospital  for  HF
in  France  in  2000  was  77  years  [5].  The  ‘‘OFICA  registry’’
[6],  which  records  data  on  patients  hospitalized  for  HF  in
France,  shows  that  one-half  of  affected  patients  are  aged
over  80  years.  In  addition,  a  sizable  number  of  hospital-
ized  patients  have  preserved  LVEF.  The  threshold  used  to
deﬁne  impaired  and  preserved  LV  function  (35%,  40%,  45%
or  50%)  is  not  clearly  deﬁned.  Nevertheless,  the  prognosis
of  HFpEF  seems  to  be  slightly  better  than  that  of  HFrEF  [7].
Whether  treatment  differs  between  patients  with  HFpEF  and
those  with  HFrEF  remains  unclear.  The  extent  to  which  car-
diologists  continue  and/or  improve  the  treatment  strategy
initiated  in  hospital  is  unknown.  It  would  also  be  interest-
ing  to  know  if  cardiologists  are  more  reluctant  to  optimize
treatment  in  patients  with  HFpEF.  These  are  some  of  the
questions  that  the  FUTURE  survey  set  out  to  answer.
The  primary  objective  of  the  FUTURE  survey  was  to  bet-
ter  describe  the  medical  treatment  of  HF  after  hospital
discharge,  according  to  LVEF.  Several  studies  of  HF  have
been  conducted  previously  in  France  (IMPROVEMENT  [8],
the  National  French  Cardiologists  survey  [5],  IMPACT-RECO
1  and  2  [9,10]  and  the  National  General  Hospitals  registry
[11]),  showing  increasing  adherence  to  guidelines  in  current
practice.  However,  none  of  these  studies  compared  groups
of  HFrEF  and  HFpEF  patients  or  analysed  the  prescriptions
made  at  the  time  of  hospital  discharge  and  afterwards  in  HF
outpatients.
Methods
The  FUTURE  study  was  a  cross-sectional  survey  with  ret-
rospective  data  collection,  conducted  in  HF  outpatients  by
French  cardiologists  in  private  practice,  between  September
2007  and  August  2008.  Physicians  were  instructed  to  enroll
the  ﬁrst  four  patients  who  satisﬁed  the  inclusion  criteria.  To
fulﬁll  these  criteria,  patients  had  to  have  been  hospitalized
within  the  previous  18  months  with  a  diagnosis  of  worsen-
ing  HF  and  not  to  be  currently  followed  by  the  participating
cardiologist.  Patients  who  were  participating  in  any  other
clinical  trial  during  the  study  period  were  not  authorized
to  participate  in  the  survey.  Neither  age  nor  LVEF  was  an
inclusion  criterion.
Cardiologists  were  asked  to  list  comorbidities,  clinical
features  of  HF  at  the  time  of  the  last  hospitalization,  the
treatment  prescribed  at  hospital  discharge,  the  patient’s
current  clinical  status  and  ongoing  treatment.  Clinical  his-
tory  and  medical  treatment(s)  were  recorded  using  the
patient  ﬁles  from  the  cardiologists’  ofﬁces.  Data  concerning
the  last  hospitalization  for  HF  were  collected  retrospec-
tively.
The  CNIL  (the  French  Commission  on  Data  Processing,
Data  Files  and  Individual  Liberties)  gave  its  consent  to  the
collection  of  patient  data.
As  the  aim  of  the  present  study  was  to  describe  the
inﬂuence  of  private  cardiologists’  practice  on  treatment
strategy,  the  analysis  of  treatments  was  restricted  to  HF
outpatients  who  visited  their  cardiologist  at  least  once
since  hospital  discharge  and  before  the  date  of  baseline
data  collection  (index  consultation).  Patients  were  divided
into  two  groups  (HFrEF  and  HFpEF)  according  to  LVEF  at
H
r
(
o357
ospital  discharge  (less  than  or  equal  to  40%,  reduced  LVEF;
ore  than  40%,  preserved  LVEF).  Treatment  of  HF  (drug[s],
osage  and  target  dose)  was  described  according  to  the  2008
SC  guidelines  for  HF  with  reduced  LVEF  [3]  (ACEIs  [except
or  perindopril,  which  is  not  recommended  for  HF  but  was
ccepted  because  it  is  widely  used  in  France  at  a  target
ose  of  4  mg/day]  or  ARBs,  beta-blockers,  loop  diuretics  and
ldosterone  antagonists,  either  alone  or  in  combination).
tatistical analysis
tatistical  analysis  was  performed  with  SAS  9.1  software
SAS  Institute,  Cary,  NC,  USA).  Results  are  presented  as
eans  ±  standard  deviations  for  continuous  variables  and
s  numbers  and  percentages  for  dichotomous  variables.  All
ests  were  two-sided  and  the  alpha  risk  was  set  at  0.05.  The
nﬂuence  of  demographic  and  clinical  variables,  as  well  as
he  characteristics  of  each  cardiologist  in  terms  of  the  prob-
bility  of  prescribing  each  therapeutic  class,  was  modelled
y  logistic  regression.  The  prevalence  of  HF  with  pre-
erved  LVEF  was  estimated  with  its  two-sided  95%  conﬁdence
nterval,  assuming  a  binomial  distribution.  Between-group
omparisons  were  performed  using  an  unpaired  Student’s  t
est  or  the  Mann—Whitney  U  test  for  continuous  data  and
 Chi2 test  or  Fisher’s  exact  test  for  categorical  variables.
ome  comparisons  were  adjusted  for  age  using  two-way
nalysis  of  variance.
esults
 total  of  1673  patients  with  a  diagnosis  of  HF  estab-
ished  during  a  previous  hospitalization  were  enrolled  by
24  cardiologists  between  September  2007  and  August  2008.
omplete  data  were  available  for  1408  patients  at  hospital
ischarge;  221  patients  were  excluded  from  the  analysis,
ainly  because  they  had  not  been  hospitalized  within  the
revious  18  months.  LVEF  at  hospital  discharge  was  not
vailable  for  44  patients.  A  total  of  1137  patients  attended
t  least  one  visit  with  their  cardiologist  between  hospital
ischarge  and  the  index  consultation.  Therefore,  patient
haracteristics  according  to  LVEF  were  described  in  1408
atients,  whereas  the  course  and  outcome  of  clinical  varia-
les  and  treatments  were  analysed  on  a  subset  of  1137
atients.
Patients  were  enrolled  in  the  survey  5.8  ±  4.5  months
fter  hospital  discharge  after  a  mean  number  of  2.3  ±  1.7
isits  to  the  cardiologists.  Average  time  between  hospital
ischarge  and  the  index  consultation  was  less  than  3  months
or  403  patients,  3—6  months  for  291  patients,  6—12  months
or  286  patients  and  more  than  12  months  for  157  patients.
haracteristics and clinical variables at
ospital discharge
or  the  1408  patients  analysed  at  hospital  discharge,  the
ean  age  was  72  ±  11  years,  65%  were  aged  over  70  years,
7%  were  men  and  the  mean  LVEF  was  40  ±  13%.  The  cause  of
F  was  ischaemic  heart  disease  in  727  patients  (52%),  arte-
ial  hypertension  in  582  (41%),  valvular  heart  disease  in  219
16%),  and  was  associated  with  primary  dilated  cardiomy-
pathy  in  462  (33%)  (more  than  one  cause  of  HF  could  be
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eported  in  a  given  patient).  Comorbidities  were  frequent
nd  included  hypertension  (65%),  diabetes  (31%),  renal  fail-
re  (35%),  asthma/COPD  (18%)  and  anaemia  (8%).  Reasons
or  hospitalization  were  a  ﬁrst  episode  of  acute  HF  (‘‘de
ovo  HF’’  according  to  the  2008  ESC  classiﬁcation  [3])  in
4%  of  patients  and  worsening  of  known  HF  in  55%.  In  33%
f  patients,  the  initial  clinical  presentation  of  HF  on  admis-
ion  to  hospital  was  acute  pulmonary  oedema.  At  hospital
ischarge,  69%  patients  had  sinus  rhythm  as  seen  on  their
lectrocardiogram.
LVEF  was  reduced  (less  than  or  equal  to  40%)  in  792
atients  (56%)  and  preserved  (more  than  40%)  in  616  (44%).
ome  characteristics  (Table  1)  were  more  frequent  in  HFpEF
atients  than  in  HFrEF  patients:  the  former  were  older  and
ore  often  were  female,  overweight  or  obese.  HF  had  been
iagnosed  more  recently  and  was  more  often  of  hyper-
ensive  or  cardiac  valvular  origin  and  anaemia  was  more
requent.  Conversely,  plasma  concentrations  of  B-type  natri-
retic  peptide  were  signiﬁcantly  more  elevated  and  renal
ailure  was  more  frequent  in  patients  with  reduced  LVEF.
owever,  no  difference  was  observed  between  the  two
roups  regarding  some  comorbidities:  ischaemic  origin  of  HF,
istory  of  stroke,  asthma/COPD  and  diabetes.  Based  on  LVEF,
w
7
H
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Table  1  Patients’  characteristics  at  hospital  discharge  (n  =  14
HFrEF  (n  =  792;  5
Age  (years)  71  ±  12  
Men  583  (74)  
BMI  (kg/m2)  26.5  ±  4.9  
Overweight/obese  308  (39)  
Time  since  diagnosis  of  HF  (years) 3.9  ±  4.9  
HF  of  ischaemic  origin 422  (53)
HF  of  hypertensive  origin 235  (30)  
HF  of  valvular  origin 95  (12)
Dilated  cardiomyopathy 348  (44)
HF  of  mixed  origin 273  (34)
History  of  stroke 66  (8)
Renal  failure 295  (37)
Asthma/COPD 146  (18)  
Anaemia 56  (7)
Diabetes  237  (30)  
Hypertension  441  (56)  
Hypercholesterolaemia  439  (55)  
Current  smokers  286  (36)  
Excessive  drinkers  148  (19)  
Sinus  rhythmc 476  (71)  
Plasma  creatinine  (mol  L−1)  106  ±  29  
Plasma  haemoglobin  (g/dL)  12.6  ±  1.7  
Plasma  BNP  (pg/mL)c,d 370  ±  1006  
CRT  110  (14.3)  
ICD  87  (11.3)  
Cardiac  pacemaker  178  (22.4)  
Data are mean ± standard deviation or number (%). BMI: body mass in
pulmonary disease; CRT: cardiac resynchronization therapy; HF: hea
patients with reduced LVEF; ICD: implantable cardiac deﬁbrillator.
a P = 0.04: comparison adjusted for sex.
b P = 0.0002: comparison adjusted for sex.
c n = 1137.
d Median ± standard deviation.A.  Cohen  Solal  et  al.
he  condition  of  HFpEF  patients  was  less  serious  at  hospital
ischarge  (Table  2).
hange  between  hospital  discharge  and  index
onsultation
unctional  status  was  analysed  in  1137  patients  who  visited
he  participating  cardiologist  between  hospital  discharge
nd  the  index  consultation.  At  hospital  discharge,  most
atients  were  in  class  II  and  III  of  the  NYHA  classiﬁcation
58%  in  class  II,  29%  in  class  III,  7%  in  class  I and  5%  in
lass  IV).  At  the  index  consultation,  functional  status  was
mproved  in  all  patients,  regardless  of  ejection  fraction
15%  in  NYHA  class  I,  63%  in  class  II,  20%  in  class  III,  2%  in
lass  IV;  P <  0.0001).  Based  on  LVEF,  the  functional  status
f  HFpEF  patients  remained  signiﬁcantly  better  (Table  2).
n  addition,  systolic  blood  pressure  was  higher  in  HFpEF
atients  compared  with  in  HFrEF  patients  (134  ±  16  mmHg
nd  124  ±  17  mmHg,  respectively;  P  <  0.0001).  Heart  rate
as  only  available  at  the  index  consultation  and  was
2.7  ±  16.3  beats/min  and  72.6  ±  15.8  beats/min  in  the
FrEF  and  HFpEF  groups,  respectively  (difference  not
igniﬁcant).
08).
6%)  HFpEF  (n  =  616;  44%)  P
74  ±  11  <  0.0001
355  (58)  <  0.0001
26.8  ±  4.8  0.23
285  (47)  0.004
2.5  ±  3.5  <  0.0001
305  (50)  0.16
347  (56)  <  0.0001
124 (20)  <  0.0001
114  (19) <  0.0001
259  (42) 0.004
56 (9) 0.62
192  (31) 0.02
112  (18)  0.90
63 (10)  0.03
201  (33)  0.28
472  (77)  <  0.0001
355  (58)  0.41
164  (27)  0.0002a
57  (9)  <  0.0001b
309  (66)  0.06
101  ±  31  0.016
12.6  ±  1.7  0.86
243  ±  591  <  0.0001
24  (4.0)  <  0.0001
12  (2.0)  <  0.0001
90  (14.6)  0.0002
dex; BNP: B-type natriuretic peptide; COPD: chronic obstructive
rt failure; HFpEF: HF patients with preserved LVEF; HFrEF: HF
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Table  2  Functional  status  at  hospital  discharge  and  index  consultation  (n  =  1137).
Hospital  discharge  Index  consultation
HFrEF  (n  =  661)  HFpEF  (n  =  476)  P  HFrEF  (n  =  661)  HFpEF  (n  =  476)  P
NYHA  I  35  (5)  44  (9)  <0.0001  84  (13)  87  (18)  <0.0001
NYHA  II  344  (53)  311  (66)  396  (60)  315  (67)
NYHA  III  226  (35)  106  (22)  158  (24)  65  (14)
NYHA  IV  43  (7)  13  (3)  19  (3)  5  (1)
Data are number (%). HFpEF: HF patients with preserved LVEF; HFrEF: HF patients with reduced LVEF; NYHA: New York Heart Association.
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ful  in  12%  of  HFpEF  patients  vs  3%  of  HFrEF  patients  (11%  vs
5%  for  ACEIs,  respectively).Therapeutic management
At  hospital  discharge
At  the  time  of  hospital  discharge,  71%  of  1137  patients
were  receiving  one  of  the  four  recommended  beta-blockers
(carvedilol,  bisoprolol,  metoprolol  CR  XL  or  nebivolol),  82%
were  receiving  an  ACEI  or  an  ARB,  87%  were  receiving  a  loop
diuretic  and  29%  were  receiving  an  aldosterone  antagonist.
Half  of  the  patients  (52.8%)  received  treatment  combining
a  beta-blocker,  an  ACEI  or  an  ARB  and  a  diuretic.  About  one-
third  of  patients  (37%)  treated  with  the  combination  of  a
beta-blocker  and  an  ACEI  or  an  ARB  received  more  than  or
equal  to  50%  of  the  target  dose  for  each  treatment  but  only
5%  of  these  patients  were  at  the  target  dose.  The  target
doses  of  HF  treatment  were  seldom  prescribed  at  hospital
discharge,  thus  allowing  cardiologists  to  titrate  treatment
further  in  the  subsequent  months.  Other  drugs  were  fre-
quently  prescribed:  cardiac  glycosides  were  given  to  17%  of
patients,  vitamin  K  antagonists  to  43%,  antiplatelet  agents
to  57%,  statins  to  60%  and  calcium  channel  blockers  to  16%.
Only  17%  of  patients  were  transferred  to  a  convalescent
ward  or  hospital  and  83%  returned  home.
According  to  the  LVEF,  regardless  of  the  HF  treatment
prescribed  (ACEI  and/or  ARB,  beta-blocker,  loop  diuretic  or
aldosterone  antagonist),  these  therapies  were  prescribed
signiﬁcantly  less  frequently  in  HFpEF  patients  but  the  dose
reached  (more  than  or  equal  to  50%  of  target  dose  or
target  dose)  was  not  different  between  the  two  groups,
except  for  beta-blockers  (Table  3).  Differences  were  also
found  for  non-drug  therapies:  a  cardiac  rehabilitation  pro-
gramme  was  initiated  less  often  in  HFpEF  patients  (13%  vs
24%;  P  <  0.0001);  stays  in  a  convalescent  ward  were  less  fre-
quent  in  HFpEF  patients  (13%  vs  19%;  P  =  0.003);  and  speciﬁc
educational  information  was  given  to  fewer  HFpEF  patients
(35%  vs  48%;  P  <  0.0001).  Only  a  few  patients  (8%)  joined  an
ambulatory  health  network  combining  private  and  hospital
physicians  (11%  of  HFrEF  patients  and  3%  of  HFrEF  patients;
P  <  0.0001).
At  the  index  consultation
Treatment  could  have  been  modiﬁed  by  the  cardiologist
at  least  once  since  hospital  discharge.  All  patients  were
treated  (Fig.  1):  74%  with  the  recommended  beta-blockers,
83%  with  an  ACEI  or  an  ARB,  86%  with  a  loop  diuretic
and  31%  with  an  aldosterone  antagonist.  The  reasons
for  not  prescribing  beta-blockers  were:  contraindications
to  these  agents  (especially  asthma/COPD)  (35%);  poor
F
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bolerance  (21%);  expectation  of  poor  tolerance  (10%);  or
eta-blockers  considered  as  being  useless  (7%).  The  reasons
or  not  prescribing  an  ACEI  were  dominated  by:  poor  toler-
nce  (occurrence  of  cough)  (57%);  contraindications  (11%);
xpectation  of  poor  tolerance  (4%);  or  ACEIs  considered  as
ot  being  useful  (8%).  The  main  reason  for  prescription  of
n  ARB  was  poor  tolerance  of  an  ACEI  (70%).  The  majority  of
atients  (62%)  received  treatment  combining  a  beta-blocker
ith  an  ACEI  or  an  ARB,  and  54%  received  the  three-drug
ombination  with  a  loop  diuretic.  Concerning  the  dosage,
6%  of  patients  treated  with  a  beta-blocker  plus  an  ACEI  or
n  ARB  received  at  least  50%  of  the  target  dose  for  each
reatment  and  15%  of  patients  reached  the  recommended
arget  doses.  Other  drugs  were  often  prescribed:  cardiac
lycosides  were  given  to  14%  of  patients,  vitamin  K antago-
ists  to  42%,  antiplatelet  agents  to  55%,  statins  to  60%  and
alcium  channel  blockers  to  15%.
According  to  the  LVEF,  as  at  hospital  discharge,  HFpEF
atients  received  beta-blockers,  ACEIs,  loop  diuretics
r  aldosterone  antagonists  signiﬁcantly  less  frequently
Table  4).  The  proportions  of  patients  who  received  a  beta-
locker  plus  an  ACEI  or  an  ARB  at  target  doses  were  similar
n  the  two  groups  (16%  in  HFrEF  patients  and  15%  in  HFpEF
atients).  Beta-blockers  were  considered  as  not  being  use-igure 1. Treatments at index consultation according to left
entricular ejection fraction (LVEF) status (n = 1137). ACEI:
ngiotensin-converting enzyme inhibitor; ARB: angiotensin receptor
locker; indpt: independent of.
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Table  3 Treatments  at  hospital  discharge  (n  =  1137).
HFrEF  (n  =  661) HFpEF  (n  =  476)  P
Beta-blockera 496  (75)  309  (65)  0.0002
At  ≥  50%  of  target  dose  272  (55)  200  (65)  0.005
At  target  dose 52 (10)  33 (11)  0.93
ACEIb 476 (72)  309 (65)  0.01
At  ≥  50%  of  target  dose 251 (53)  159 (51)  0.73
At  target  dose 242 (51)  157 (51)  0.99
ARBc 91  (14)  76  (16)  0.30
At  ≥  50%  of  target  dose  46  (51)  39  (51)  0.92
At  target  dose  4  (4)  3  (4)  1.00
ACEI  or  ARB  559  (85)  377  (79)  0.02
At  ≥  50%  of  target  dose  309  (54)  199  (53)  0.71
At  target  dose  245  (44)  160  (42)  0.67
Loop  diuretics  595  (90)  393  (83)  0.0002
Antialdosteroned 220  (33)  104  (22)  <0.0001
Combination  of  ACEI  or  ARB  and  beta-blocker  422  (64)  253  (53)  0.0003
At  ≥  50%  of  target  dose  147  (35)  105  (42)  0.08
At  target  dose  20  (5)  15  (6)  0.90
Data are number (%). Percentage attaining target dose is based on number of patients on treatment. ACEI: angiotensin-converting
enzyme inhibitor; ARB: angiotensin receptor blocker; HFpEF: HF patients with preserved LVEF; HFrEF: HF patients with reduced LVEF.
a Metoprolol, nebivolol, bisoprolol, carvedilol.
b Captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril (at accepted 4 mg target dose).
c Candesartan, valsartan.
d Spironolactone or eplerenone.
C
a
A
mhange  in  treatment  between  hospital  discharge
nd the  index  consultation
t  the  index  consultation,  HF  medical  treatment  had  been
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Table  4  Treatments  at  index  consultation  (n  =  1137).
HFrEF
Beta-blockera 512  (7
At  ≥  50%  of  target  dose  298  (5
At  target  dose  103  (2
ACEIb 473  (7
At  ≥  50%  of  target  dose  407  (8
At  target  dose  291  (6
ARBc 107  (1
At  ≥  50%  of  target  dose  60  (5
At  target  dose  10  (9
ACEI  or  ARB  566  (8
At  ≥  50%  of  target  dose  459  (8
At  target  dose  299  (5
Loop  diuretics  590  (8
Antialdosteroned 238  (3
Combination  of  ACEI  or  ARB  and  beta-blocker  443  (6
At  ≥  50%  of  target  dose  235  (5
At  target  dose  70  (1
Data are number (%). Percentage attaining target dose is based on 
enzyme inhibitor; ARB: angiotensin receptor blocker; HFpEF: HF patien
a Metoprolol, nebivolol, bisoprolol, carvedilol.
b Captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril (at
c Candesartan, valsartan.
d Spironolactone or eplerenone.nd  replaced  due  to  adverse  events  or  hypotension  and
thers  were  added  as  the  result  of  clinical  impairment
Tables  5  and  6).  A  beta-blocker  was  added  in  85  out  of
32  patients  not  treated  with  beta-blockers  at  discharge  and
 (n  =  661)  HFpEF  (n  =  476)  P
7)  329  (69)  0.002
8)  221  (67)  0.009
0)  70  (21)  0.68
2)  295  (62)  0.0007
6)  260  (88)  0.40
2)  168  (57)  0.21
6)  98  (21)  0.06
6)  51  (52)  0.56
)  5  (5)  0.24
6)  382  (80)  0.02
1)  306  (80)  0.70
3)  173  (45)  0.02
9)  393  (83)  0.001
6)  112  (24)  <  0.0001
7)  267  (56)  0.0002
3)  162  (61)
6)  39  (15)
number of patients on treatment. ACEI: angiotensin-converting
ts with preserved LVEF; HFrEF: HF patients with reduced LVEF.
 accepted 4 mg target dose).
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Table  5  Evolution  of  heart  failure  treatment  since  hospital  discharge  in  patients  with  left  ventricular  ejection  fraction
less  than  or  equal  to  40%.
Time  between  hospital  discharge  and  index  consultation
<  3  months
(n  =  237)
3 to  6  months
(n  =  171)
6  to  12  months
(n  =  156)
> 12  months
(n  =  97)
Beta-blocker  added  10  (15)  10  (26)  15  (43)  9  (35)
Beta-blocker  stopped  7  (4)  10  (8)  5  (4)  6  (8)
Balance  beta-blocker  +3  0  +10  +3
ACEI  addeda 15  (21)  5  (11)  6  (15)  1  (4)
ACEI  stoppeda 8  (5)  9  (7)  4  (3)  9  (13)
Balance  ACEI +7  —4  +2  —8
ARB  addedb 10  (5)  8  (5)  3  (2)  6  (7)
ARB  stoppedb 3  (9)  1  (4)  3  (16)  4  (27)
Balance  ARB +7  +7  0  +2
Balance  ACEI  or  ARB  +14  +3  +2  —6
Data are number or number (%). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.
a Captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril (at accepted target 4 mg dose).
b Candesartan, valsartan.
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cstopped  in  49  out  of  805  patients  receiving  beta-blockers  at
discharge,  with  a  resultant  positive  balance  of  36  patients
(Fig.  2).  There  was  a  positive  balance  of  21  patients  for
ACEIs  or  ARBs.  The  balance  was  negative  for  ACEIs  and  pos-
itive  for  ARBs:  an  ACEI  was  added  in  46  out  of  352  patients
but  stopped  in  63  out  of  785  and  an  ARB  was  added  in  54
out  of  970  patients  and  stopped  in  16  out  of  176.  With  the
exception  of  patients  in  whom  ACEIs  were  stopped,  no  dif-
ference  in  optimization  of  medical  treatment  after  hospital
discharge  was  found  based  on  LVEF  at  hospital  discharge,
suggesting  that  the  cardiologists’  therapeutic  practices  did
not  differ  according  to  LVEF.
Cardiologists  also  increased  the  doses  of  drugs
(Tables  7  and  8).  There  was  a  positive  balance  for  all
drugs.  Among  the  756  patients  receiving  a  beta-blocker
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Table  6  Evolution  of  heart  failure  treatment  since  hospital  di
more  than  40%.
Time  between  hospital  dischar
<  3  months
(n  =  166)
3 to  6  m
(n  =  120)
Beta-blocker  added  9  (15)  9  (23)  
Beta-blocker  stopped  9  (9)  6  (8)  
Balance  beta-blocker  0  +3  
ACEI  addeda 8  (12)  4  (11)  
ACEI  stoppeda 8  (8)  6  (7)  
Balance  ACEI  0  —2  
ARB  addedb 10  (7)  4  (4)  
ARB  stoppedb 2  (7)  1  (7)  
Balance  ARB  +8  +3  
Balance  ACEI  or  ARB  +8  +1  
Data are number or number (%). ACEI: angiotensin-converting enzyme 
a Captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril (at
b Candesartan, valsartan.ince  hospital  discharge  until  entry  in  the  survey,  doses
ere  increased  in  218  cases  and  decreased  in  27,  resulting
n  a  positive  balance  of  191  patients  (Fig.  2).  Among  the
22  patients  receiving  an  ACEI,  doses  were  increased  in  99
ases  and  decreased  in  30  (positive  balance  of  69  patients).
n  the  151  patients  treated  with  an  ARB,  the  doses  were
ncreased  in  23  cases  and  decreased  in  three  (positive
alance  of  20  patients).  No  difference  was  found  between
FrEF  and  HFpEF  patients.  The  reasons  for  not  having
eached  target  dose  were:  satisfactory  control  with  the
urrent  regimen  (24%  for  beta-blockers,  26%  for  ACEIs,  27%
or  ARBs),  ongoing  current  titration  (32%  for  beta-blockers,
7%  for  ACEIs,  28%  for  ARBs),  higher  doses  poorly  tolerated
42%  for  beta-blockers,  40%  for  ACEIs,  38%  for  ARBs)  or
oncern  for  possible  adverse  events  with  higher  doses  (16%
scharge  in  patients  with  left  ventricular  ejection  fraction
ge  and  index  consultation
onths 6  to  12  months
(n  =  130)
> 12  months
(n  =  60)
14  (31)  9  (43)
3  (4)  3  (8)
+11  +6
5  (11)  2  (13)
15  (18)  4  (9)
—10  —2
9  (8)  4  (8)
1  (4)  1  (11)
+8  +3
—2  +1
inhibitor; ARB: angiotensin receptor blocker.
 accepted target 4 mg dose).
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Table  7  Evolution  of  heart  failure  treatment  dosing  since  hospital  discharge  in  patients  with  left  ventricular  ejection
fraction  less  than  or  equal  to  40%.
Time  between  hospital  discharge  and  the  index  consultation
<  3  months
(n  =  237)
3 to  6  months
(n  =  171)
6 to  12  months
(n  =  156)
> 12  months
(n  =  97)
Beta-blocker  dose  increaseda 34  (20)  42  (32)  37  (31)  25  (35)
Beta-blocker  dose  decreaseda 7  (4)  4  (3)  6  (5)  4  (6)
Balance  +27  +38  +31  +21
ACEI  dose  increasedb 16  (10)  20  (16)  19  (16)  11  (15)
ACEI  dose  decreasedb 5  (3)  7  (6)  8  (7)  1  (1)
Balance  +11  +13  +11  +10
ARB  dose  increasedc 2  (6)  2  (9)  4  (21)  2  (13)
ARB  dose  decreasedc 0  0  0  0
Balance +2  +2  +4  +2
Data are number or number (%). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.
a Metoprolol, nebivolol, bisoprolol, carvedilol.
b Captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril (at accepted 4 mg target dose).
c Candesartan, valsartan.
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ior  beta-blockers,  16%  for  ACEIs,  14%  for  ARBs).  The  number
f  patients  who  reached  the  target  dose  with  combination
herapy  for  HF  (ACEI  or  ARB  plus  beta-blocker)  was  tripled
ompared  with  that  at  hospital  discharge  but  remained
ow  (15%).  However,  the  majority  of  these  patients  (56%)
eceived  at  least  50%  of  the  target  dose  for  each  treatment.
There  does  not  seem  to  be  a  major  interaction  between
he  time  between  hospital  discharge  and  index  consulta-
ion,  and  the  treatment  or  dose  of  treatment  at  the  index
onsultation  (Tables  5—8).  It  seems  that  the  addition  of  beta-
lockers  was  increased  in  patients  seen  for  the  ﬁrst  time
etween  6  and  12  months,  but  our  survey  does  not  permit
s  to  know  if  this  introduction  was  made  early  or  late  after
ischarge.
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Table  8  Evolution  of  heart  failure  treatment  dosing  since  ho
fraction  more  than  40%.
Time  between  hospital  d
<  3  months
(n  =  166)
3 to  
(n  =  1
Beta-blocker  dose  increaseda 26  (25)  20  (2
Beta-blocker  dose  decreaseda 0  (0)  1  (1)
Balance  +26  +19  
ACEI  dose  increasedb 8  (8)  6  (7)
ACEI  dose  decreasedb 4  (4)  4  (5)
Balance  +4  +2  
ARB  dose  increasedc 3  (10)  6  (40
ARB  dose  decreasedc 2  (7)  0  (0)
Balance  +1  +6  
Data are number or number (%). ACEI: angiotensin-converting enzyme 
a Metoprolol, nebivolol, bisoprolol, carvedilol.
b Captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril (at
c Candesartan, valsartan.iscussion
his  survey  on  the  management  of  HF  with  medical  treat-
ent  by  cardiologists  in  France  is  the  ﬁrst  of  its  kind.
ndeed,  although  the  treatment  of  HFrEF  patients  is  becom-
ng  increasingly  better  understood,  the  treatment  of  HFpEF
atients  is  much  less  so.  Drug  treatment  of  HF  should
e  based  on  the  available  guidelines.  But  the  recommen-
ations  of  the  ESC  regarding  the  treatment  of  HF  were
stablished  primarily  for  patients  [3].  Because  of  the  lim-
ted  evidence-based  medicine  on  the  optimal  treatment  of
FpEF,  recommendations  on  the  treatment  of  these  patients
o  which  the  cardiologist  may  refer  are  much  less  pre-
ise.  The  purpose  of  this  study  was  to  determine  how
spital  discharge  in  patients  with  left  ventricular  ejection
ischarge  and  the  index  consultation
6  months
20)
6 to  12  months
(n  =  130)
> 12  months
(n  =  60)
5)  22  (26)  12  (31)
 4  (5)  1  (3)
+18  +11
 12  (14)  7  (16)
 1  (1)  0  (0)
+11  +7
)  3  (13)  1  (11)
 0  (0)  1  (11)
+3  0
inhibitor; ARB: angiotensin receptor blocker.
 accepted 4 mg target dose).
Optimization  of  HF  treatment  after  discharge  according  to  LVEF  
Figure 2. Change in beta-blocker treatment since hospital dis-
charge according to left ventricular ejection fraction (LVEF) status
(n = 1137). BB: beta-blockers (metoprolol, nebivolol, bisoprolol,
carvedilol). *Percentages based on number of patients without
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ctreatment at hospital discharge. **Percentages based on number of
patients on treatment at hospital discharge.
cardiologists  in  private  practice  manage  HF  patients  after
discharge  from  the  hospital,  taking  into  account  LVEF.
The  FUTURE  survey  has  some  original  features  com-
pared  with  previous  studies  conducted  in  France.  Unlike
the  IMPACT-RECO  studies  [9,10], it  included  patients  with
HF  regardless  of  LVEF.  Moreover,  the  assessment  of  medical
therapy  was  performed  at  two  successive  time  points  (at  the
time  of  hospital  discharge  and  at  the  index  consultation)  and
we  have  precise  information  on  the  doses  of  drugs.
Patient characteristics
Clinical  data  on  HF  patients  at  hospital  discharge  conﬁrmed
what  has  previously  been  reported,  particularly  with  regard
to  HF  (HF  more  often  affects  elderly  subjects  with  fre-
quent  comorbidities)  and  more  particularly  with  regard  to
HFpEF  patients  —  a  higher  prevalence  of  elderly  subjects
and  women  in  particular  was  found  in  this  group.  The  shorter
duration  of  the  disease  in  the  HFpEF  patient  group  is  prob-
ably  attributable  to  the  higher  incidence  of  hypertension
in  this  group.  HF  progresses  more  often  by  repeated  brief
episodes  of  acute  HF  decompensation  (‘‘transient  HF’’  as
deﬁned  in  the  2008  ESC  guidelines)  than  by  chronic  HF.  This
probably  also  explains  the  lower  concentrations  of  B-type
natriuretic  peptide  found  at  hospital  discharge  in  this  pop-
ulation.  It  is  interesting  to  note  the  frequency  of  valvular
heart  disease  (20%),  arrhythmias  (34%)  and  combined  aeti-
ologies  (42%),  which  were  higher  in  the  HFpEF  group  than  in
the  HFrEF  group.  In  the  context  of  clinical  trials  to  evaluate
a  drug  in  HFpEF  patients,  a  high  percentage  of  these  patients
would  not  be  eligible  due  to  the  usual  inclusion  or  exclusion
criteria  used  in  HF  trials  [4]  (elderly  subjects,  valvular  heart
disease,  arrhythmia,  etc.).
Therapeutic management in heart failure
outpatientsThe  time  between  hospital  discharge  and  inclusion  in  the
survey  is  interesting  to  consider  (i.e.  about  6  months
after  discharge,  patients  paid  two  visits  to  their  cardiolo-
gist  on  average).  This  can  be  considered  very  satisfactory
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also  taking  into  account  the  fact  that  the  analysis  was  lim-
ted  to  patients  who  visited  the  cardiologist  at  least  once
ince  hospital  discharge  and  that  the  inclusion  period  was  18
onths).  In  contrast,  only  28%  of  patients  visited  their  car-
iologist  during  the  ﬁrst  3  months.  This  may  be  considered
s  an  unreasonable  delay,  as  the  majority  of  readmissions
o  hospital  are  known  to  occur  within  the  ﬁrst  weeks  after
ospital  discharge  [12].
The ﬁndings  of  the  FUTURE  survey  provide  a  repre-
entative  snapshot  of  treatment  of  HF,  with  satisfactory
anagement  of  patients  and  high  rates  of  prescription  of
eta-blockers  and  ACEIs  or  ARBs.  With  regard  to  HFrEF,  our
ata  show  a  slight  improvement  compared  with  the  IMPACT-
ECO  1  and  2  studies  [9,10]  carried  out  between  2004  and
006.  Concerning  the  use  of  beta-blockers,  the  rate  of  pres-
ription  increased  and  is  now  higher  than  that  of  ACEIs.
owever,  it  has  peaked  at  75—80%,  reﬂecting  perhaps  a  ﬁg-
re  that  is  difﬁcult  to  surpass.  This  is  true  primarily  due
o  contraindications  involving  mainly  the  respiratory  sys-
em  and  the  risk  of  severe  bradycardia  in  the  elderly,  and
he  lack  of  formal  systematic  indications  for  beta-blockers
n  HFpEF.  Moreover,  the  prescription  of  beta-blockers  and
enin-angiotensin  system  antagonists  was  already  high  at
he  time  of  hospital  discharge  in  our  survey,  leaving  rela-
ively  little  room  for  cardiologists  to  increase  the  number  of
rescriptions.
Data  on  the  management  of  HFpEF  patients  have  an  orig-
nal  aspect  in  several  respects.  It  can  again  be  noted  that
ost  of  the  ﬁndings  were  recorded  at  the  time  of  hos-
ital  discharge.  There  was  a  high  rate  of  prescription  of
eta-blockers  and  ACEIs  or  ARBs,  while  recommendations
egarding  these  drugs  in  this  indication  are  not  so  broad  as
o  justify  these  prescription  rates  [3].  The  results  seemed
o  indicate  that  the  combination  of  a  beta-blocker  and  an
CEI  or  an  ARB  was  the  rule  once  a  diagnosis  of  HF  was
stablished,  regardless  of  LVEF.  However,  evidence-based
edicine  regarding  the  efﬁcacy  of  ACEIs  or  ARBs  [13—16]
nd  beta-blockers  [13,17]  on  robust  endpoints  is  lack-
ng.  Furthermore,  our  investigation  targeted  beta-blockers
uthorized  in  France  in  HF;  if  we  also  considered  other
idely  used  beta-blockers  in  France,  such  as  atenolol  or
cebutolol,  prescription  rates  for  beta-blockers  in  HFpEF
atients  would  be  extremely  high.  Similarly,  the  rate  of
rescription  of  aldosterone  antagonists,  which  were  only
ndicated  in  NYHA  classes  III  and  IV  systolic  HF  at  the  time  of
he  survey,  may  appear  illogical  in  these  patients.  However,
n  France,  spironolactone  has  an  indication  for  treatment  of
iuretic-induced  hypokalaemia,  whatever  the  cause,  which
ould  explain  some  of  the  prescriptions.
oses of heart failure treatment
ur  survey  is  the  ﬁrst  in  France  carried  out  on  the  doses
f  drugs  for  HF  at  hospital  discharge  and  in  outpatient  pri-
ate  practice.  In  HFrEF,  we  noted  that  the  prescribed  doses
ere  relatively  low  with  regard  to  beta-blockers  and  ACEIs.
lthough  it  is  conceivable  that,  at  the  time  of  hospital  dis-
harge,  the  doses  of  beta-blockers  prescribed  were  far  from
he  target  doses  recommended  by  scientiﬁc  societies,  the
xplanation  is  less  acceptable  for  ACEIs  or  ARBs.  In  contrast,
t  the  inclusion  visit,  several  months  after  hospital  discharge
nd  after  at  least  two  ofﬁce  visits,  we  would  expect  the
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rescription  of  higher  doses  of  these  drugs.  Although  the
ate  of  prescription  of  the  combination  of  beta-blockers  and
n  ACEI  or  an  ARB  at  recommended  target  doses  tripled
etween  hospital  discharge  and  index  consultation,  less  than
0%  of  HFrEF  patients  reached  the  recommended  target
ose  for  each  treatment  at  a  distance  from  hospital  dis-
harge.  We  may  ask  why  the  recommended  target  doses
ere  not  reached.  In  about  30%  of  cases,  the  absence  of
rescribing  an  increase  was  justiﬁed  by  reported  intoler-
nce  to  beta-blocker  therapy  but  also  simply  out  of  concern
or  possible  intolerance  or  that  such  therapy  was  not  use-
ul.  It  seems  important  to  consider  this  concern  about  lack
f  usefulness  or  suspected  intolerance  to  higher  doses  of
hese  treatments,  particularly  beta-blockers.  This  is  a  real
roblem  in  everyday  practice  that  is  rarely  acknowledged
y  physicians  but  needs  to  be  overcome.  The  FUTURE  study
howed  that  there  is  always  apprehension  of  an  adverse
vent:  cardiologists  prefer  to  stop  increasing  the  dose  of
 drug  before  intolerance  to  it  occurs,  especially  in  ambu-
atory  practice  where  some  adverse  events  (bradycardia
nd/or  hypotension)  are  less  easily  manageable  than  in  the
ospital.  Second,  the  concept  of  the  ‘‘futility’’  of  increasing
he  dose  of  a  drug  shows  that  the  strategy  of  increasing  the
osage  until  the  maximum  tolerated  dose  and  not  accord-
ng  to  the  well-being  of  the  patient  is  not  fully  integrated
r  accepted.  In  HFpEF,  the  same  trends  are  observed  while
o  recommendations  exist  to  increase  the  dose  until  the
aximum  tolerated  dose  in  this  indication.
tudy limitations
he  FUTURE  survey  was  an  observational  cross-sectional
urvey  conducted  in  HF  outpatients  followed  by  cardiol-
gists  in  private  practice  with  retrospective  collection  of
ata  at  hospital  discharge.  Therefore,  it  does  not  provide
n  insight  into  the  management  of  HF  by  general  practi-
ioners.  Moreover,  although  the  cardiologists  were  randomly
elected  from  the  French  database,  we  cannot  exclude  a
election  bias  with  inclusion  of  a  selected  HF  population.
ata  were  self  reported  by  cardiologists  but  quality  con-
rol  was  performed  randomly  in  10%  of  centres,  focused  on
linical  characteristics  and  HF  medical  treatment.  All  data
ollected  and  reported  by  private  cardiologists  conformed
o  medical  records  in  the  study  centres.  The  precise  date  of
ddition  of  therapy  after  discharge  could  not  be  determined.
e  enrolled  all  HF  outpatients,  whatever  their  LVEF,  age  or
omorbidities.  Therefore,  our  population  was  not  similar  to
hat  usually  included  in  large  HF  clinical  trials.  The  LVEF  cut-
ff  for  separating  the  HFrEF  and  HFpEF  group  was  arbitrary,
ased  mainly  on  the  CHARM  data,  and  other  cut-offs  may
lso  have  been  considered.
onclusion
n  conclusion,  the  FUTURE  survey  demonstrated  a  simi-
ar  approach  to  the  treatment  of  HF,  regardless  of  LVEF.
his  raises  the  question  of  how  cardiologists  integrate  the
oncept  of  different  forms  of  HF  and  its  management
epending  on  the  level  of  LVEF.
Overall,  the  rate  of  prescription  of  therapies  for  HF,
onstantly  rising,  now  appears  to  be  relatively  satisfactory
[A.  Cohen  Solal  et  al.
nd  it  will  probably  be  difﬁcult  to  increase  such  prescrip-
ions  due  to  contraindications  or  side  effects.  The  latter
re  more  frequent  under  conditions  of  everyday  practice  in
lder  patients  with  frequent  comorbidities,  rather  than  in
linical  trials.
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